Ng CS - Search Results

1

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.

Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Davies MA, et al. Among authors: ng cs. Clin Cancer Res. 2012 Feb 15;18(4):1120-8. doi: 10.1158/1078-0432.CCR-11-2436. Epub 2012 Jan 5. Clin Cancer Res. 2012. PMID: 22223528 Free PMC article. Clinical Trial.

2

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Crane CH, et al. J Clin Oncol. 2006 Mar 1;24(7):1145-51. doi: 10.1200/JCO.2005.03.6780. J Clin Oncol. 2006. PMID: 16505434 Clinical Trial.

3

Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma.

Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, Cormier JN, Lee JE, Ross MI, Mansfield PF. Aloia TA, et al. Among authors: ng cs. J Clin Oncol. 2006 Jun 20;24(18):2858-65. doi: 10.1200/JCO.2006.05.6176. J Clin Oncol. 2006. PMID: 16782925

4

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.

Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Tannir NM, et al. Among authors: ng cs. Cancer. 2006 Nov 1;107(9):2254-61. doi: 10.1002/cncr.22253. Cancer. 2006. PMID: 17029276 Free article. Clinical Trial.

5

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.

Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Yao JC, et al. J Clin Oncol. 2008 Mar 10;26(8):1316-23. doi: 10.1200/JCO.2007.13.6374. J Clin Oncol. 2008. PMID: 18323556 Clinical Trial.

6

Phase II trial of curcumin in patients with advanced pancreatic cancer.

Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Dhillon N, et al. Among authors: ng cs. Clin Cancer Res. 2008 Jul 15;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024. Clin Cancer Res. 2008. PMID: 18628464 Clinical Trial.

7

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.

Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. Tannir NM, et al. Among authors: ng cs. J Urol. 2008 Sep;180(3):867-72; discussion 872. doi: 10.1016/j.juro.2008.05.017. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635226 Free PMC article. Clinical Trial.

8

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Kim KB, et al. Among authors: ng cs. Br J Cancer. 2008 Sep 2;99(5):734-40. doi: 10.1038/sj.bjc.6604482. Epub 2008 Aug 19. Br J Cancer. 2008. PMID: 18728664 Free PMC article. Clinical Trial.

9

Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.

Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Kim KB, et al. Cancer Chemother Pharmacol. 2009 Jun;64(1):161-7. doi: 10.1007/s00280-008-0861-0. Epub 2008 Nov 11. Cancer Chemother Pharmacol. 2009. PMID: 19002462 Clinical Trial.

10

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Tsimberidou AM, et al. Among authors: ng cs. Cancer Chemother Pharmacol. 2010 Jan;65(2):235-41. doi: 10.1007/s00280-009-1027-4. Cancer Chemother Pharmacol. 2010. PMID: 19484470 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

743 results

Search Page

Filters